论文部分内容阅读
成人急性淋巴细胞白血病(ALL)患者常规化疗的早期完全缓解(CR)率可接近75%,但远期疗效并不满意,长期无病生存率(DFS)仅为20%~35%~([1])。因高龄患病、发病时外周血高白细胞、对原诱导方案耐药、异常的基因表达或患者依从性差等不良因素影响,临床上仍有部分患者不能达到CR或在达到CR后又复发,导致预后不良,长期生存率较低。本研究通过回顾性分析11例复发难治成人ALL患者
In patients with adult acute lymphoblastic leukemia (ALL), the rate of early complete remission (CR) is close to 75%, but the long-term efficacy is not satisfactory, and the long-term disease-free survival rate is only 20% -35% 1]). Due to age-related diseases, the incidence of peripheral blood leukocytes, the original induction of resistance programs, abnormal gene expression or poor compliance of patients and other adverse factors, the clinical still some patients can not reach CR or CR after recurrence, resulting in Poor prognosis, lower long-term survival. This study retrospectively analyzed 11 cases of refractory adult ALL patients